Spondyloarthritis & psoriatic arthritis
Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence
Authors' conclusion
Complex changes in the properties of circulating neutrophils occur with secukinumab treatment in PsA that may indicate altered responsiveness to changes in both local and systemic levels of pro-inflammatory cytokines. However, host defence processes of neutrophils were unaltered.
Study context
- Population
- Patients with active PsA treated with secukinumab
- Participants
- 19 patients
- Comparison
- PsA patients treated with secukinumab vs age- and sex-matched healthy controls, and baseline vs during therapy
- PsAn = 19
- Outcome
- Peripheral blood neutrophil function (apoptosis, receptor expression, phagocytosis/killing, chemotaxis and RNA expression)
- Follow-up
- 12 week intervals for 48 weeks
Methodological detailslongitudinal, 12 week intervals for 48 weeks, age- and sex-matched healthy controls
- Longitudinal, 12 week intervals for 48 weeks
- Age- and sex-matched healthy controls
Main finding
As reported in the abstract
Neutrophil function
- At baseline, no differences in PsA neutrophil ROS generation, constitutive or cytokine-delayed apoptosis, chemotaxis or phagocytosis of opsonized Staphylococcus aureus vs healthy controls
- No differences in these functions from baseline to 12 weeks of therapy
- Surface CD11b/CD18 and CD63 increased and CD16 expression decreased during therapy
- In early (12 week) responders, RNA sequencing: transcriptome changes predicting down-regulation of cytokine signalling and chemotaxis pathways and up-regulation of de novo gene expression pathways (translation initiation, mRNA catabolism, translation)
Further findings
- PsA Response Criteria (PsARC) response · 12 weeks — PsA
- 75%
- 90% Psoriasis Area and Severity Index (PASI) response · 12 weeks — PsA
- 71%
- PsARC response: 12/16 patients; 100% at 36 weeks
- 90% PASI response: 10/14 patients
Original publication
Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence. Rheumatology (Oxford). Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →